IL136511A0 - Genetically engineered mhc molecules - Google Patents

Genetically engineered mhc molecules

Info

Publication number
IL136511A0
IL136511A0 IL13651100A IL13651100A IL136511A0 IL 136511 A0 IL136511 A0 IL 136511A0 IL 13651100 A IL13651100 A IL 13651100A IL 13651100 A IL13651100 A IL 13651100A IL 136511 A0 IL136511 A0 IL 136511A0
Authority
IL
Israel
Prior art keywords
component
cells
polypeptide
class
zeta
Prior art date
Application number
IL13651100A
Other languages
English (en)
Original Assignee
Gavish Galilee Bio Appl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gavish Galilee Bio Appl Ltd filed Critical Gavish Galilee Bio Appl Ltd
Priority to IL13651100A priority Critical patent/IL136511A0/xx
Priority to DE60143799T priority patent/DE60143799D1/de
Priority to AU74439/01A priority patent/AU7443901A/en
Priority to US10/297,060 priority patent/US7319143B2/en
Priority to PCT/IL2001/000506 priority patent/WO2001091698A2/en
Priority to AT01940953T priority patent/ATE494004T1/de
Priority to IL15309101A priority patent/IL153091A0/xx
Priority to EP01940953A priority patent/EP1301202B1/de
Publication of IL136511A0 publication Critical patent/IL136511A0/xx
Priority to IL153091A priority patent/IL153091A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL13651100A 2000-06-01 2000-06-01 Genetically engineered mhc molecules IL136511A0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IL13651100A IL136511A0 (en) 2000-06-01 2000-06-01 Genetically engineered mhc molecules
DE60143799T DE60143799D1 (de) 2000-06-01 2001-05-31 Genetisch hergestellte mhc moleküle
AU74439/01A AU7443901A (en) 2000-06-01 2001-05-31 Genetically-engineered mhc molecules
US10/297,060 US7319143B2 (en) 2000-06-01 2001-05-31 Genetically-engineered MHC molecules
PCT/IL2001/000506 WO2001091698A2 (en) 2000-06-01 2001-05-31 Genetically-engineered mhc molecules
AT01940953T ATE494004T1 (de) 2000-06-01 2001-05-31 Genetisch hergestellte mhc moleküle
IL15309101A IL153091A0 (en) 2000-06-01 2001-05-31 Genetically engineered mhc molecules
EP01940953A EP1301202B1 (de) 2000-06-01 2001-05-31 Genetisch hergestellte mhc moleküle
IL153091A IL153091A (en) 2000-06-01 2002-11-26 GENETICALLY ENGINEERED ??2-MICROGLOBULIN - CD3-?é MOLECULES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL13651100A IL136511A0 (en) 2000-06-01 2000-06-01 Genetically engineered mhc molecules

Publications (1)

Publication Number Publication Date
IL136511A0 true IL136511A0 (en) 2001-06-14

Family

ID=11074209

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13651100A IL136511A0 (en) 2000-06-01 2000-06-01 Genetically engineered mhc molecules
IL153091A IL153091A (en) 2000-06-01 2002-11-26 GENETICALLY ENGINEERED ??2-MICROGLOBULIN - CD3-?é MOLECULES

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL153091A IL153091A (en) 2000-06-01 2002-11-26 GENETICALLY ENGINEERED ??2-MICROGLOBULIN - CD3-?é MOLECULES

Country Status (7)

Country Link
US (1) US7319143B2 (de)
EP (1) EP1301202B1 (de)
AT (1) ATE494004T1 (de)
AU (1) AU7443901A (de)
DE (1) DE60143799D1 (de)
IL (2) IL136511A0 (de)
WO (1) WO2001091698A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1507550A1 (de) * 2002-05-30 2005-02-23 Sloan Kettering Institute For Cancer Research Suizid-tetramere mit mhc klasse i und ihre verwendungen
US20060003315A1 (en) * 2002-06-12 2006-01-05 Gavish-Galilee Bio Applications Ltd. Membrane-anchored beta2 microglobulin covalently linked to mhc class 1 peptide epitopes
CA2595462A1 (en) * 2005-01-21 2006-07-27 Nalan Utku Hla fusion molecules and uses thereof
KR102243575B1 (ko) * 2010-12-09 2021-04-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
WO2012127464A2 (en) 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
EP3744736A1 (de) 2013-02-20 2020-12-02 Novartis AG Effektives targeting primärer humaner leukämie mit durch den chimären anti-cd123-antigen-rezeptor veränderten t-zellen
KR102313997B1 (ko) 2013-02-20 2021-10-20 노파르티스 아게 인간화 항-EGFRvIII 키메라 항원 수용체를 사용한 암의 치료
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
AU2014366047B2 (en) 2013-12-19 2021-03-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
ES2963718T3 (es) 2014-01-21 2024-04-01 Novartis Ag Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
HRP20240874T1 (hr) 2014-04-07 2024-10-11 Novartis Ag Liječenje raka korištenjem kimernog antigenskog receptora anti-cd19
AU2015292811B2 (en) 2014-07-21 2019-12-19 Novartis Ag Treatment of cancer using a CLL-1 chimeric antigen receptor
MX2017001011A (es) 2014-07-21 2018-05-28 Novartis Ag Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
CA2955154C (en) 2014-07-21 2023-10-31 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
ES2791248T3 (es) 2014-08-19 2020-11-03 Novartis Ag Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
AU2015317608B2 (en) 2014-09-17 2021-03-11 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
RU2743657C2 (ru) 2014-10-08 2021-02-20 Новартис Аг Биомаркеры, прогнозирующие способность к терапевтическому ответу на терапию химерным рецептором антигена, и их применение
WO2016109410A2 (en) 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
RU2752918C2 (ru) 2015-04-08 2021-08-11 Новартис Аг Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) k cd19
EP3283619B1 (de) 2015-04-17 2023-04-05 Novartis AG Verfahren zur verbesserung der wirksamkeit und expansion chimärer antigen-rezeptor-exprimierender zellen
CN109476722A (zh) 2015-07-21 2019-03-15 诺华股份有限公司 用于改善免疫细胞的功效和扩张的方法
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
JP6905163B2 (ja) 2015-09-03 2021-07-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア サイトカイン放出症候群を予測するバイオマーカー
IL295858A (en) 2015-12-04 2022-10-01 Novartis Ag Preparations and methods for immuno-oncology
JP7082055B2 (ja) 2015-12-22 2022-06-07 ノバルティス アーゲー 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体（ｃａｒ）およびｐｄ－ｌ１阻害剤に対する抗体
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
TW202340473A (zh) 2016-10-07 2023-10-16 瑞士商諾華公司 利用嵌合抗原受體之癌症治療
EP3601561A2 (de) 2017-03-22 2020-02-05 Novartis AG Zusammensetzungen und verfahren zur immunonkologie
WO2019051001A1 (en) * 2017-09-06 2019-03-14 California Institute Of Technology SIGNALING AND BIFUNCTIONAL RECEPTORS HAVING ANTIGENS (SABR)
EP3697436A1 (de) 2017-10-18 2020-08-26 Novartis AG Zusammensetzungen und verfahren für selektiven proteinabbau
WO2019209631A1 (en) * 2018-04-23 2019-10-31 Baylor College Of Medicine Chimeric hla accessory receptor
WO2019210281A1 (en) * 2018-04-27 2019-10-31 Casebia Therapeutics Limited Liability Partnership Methods and compositions of cytotoxic t cell depletion
SG11202011830SA (en) 2018-06-13 2020-12-30 Novartis Ag Bcma chimeric antigen receptors and uses thereof
WO2020097188A1 (en) * 2018-11-06 2020-05-14 Sangamo Therapeutics, Inc. Identification of molecules for inhibition of nk-mediated cell killing
US11975026B2 (en) 2019-11-26 2024-05-07 Novartis Ag CD19 and CD22 chimeric antigen receptors and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2096749T3 (es) * 1990-12-14 1997-03-16 Cell Genesys Inc Cadenas quimericas para vias de transduccion de señal asociada a un receptor.
AU7010996A (en) 1995-08-30 1997-03-19 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Selective elimination of t cells that recognize specific preselected targets
DE19545351C1 (de) * 1995-12-05 1997-07-31 Univ Ludwigs Albert Eukaryotische Zellen mit Hybridrezeptor und dadurch steuerbarem Genkonstrukt, Verfahren zu deren Herstellung und Verwendung dieser Zellen in der Gentherapie

Also Published As

Publication number Publication date
IL153091A (en) 2011-01-31
US20040137562A1 (en) 2004-07-15
EP1301202A2 (de) 2003-04-16
US7319143B2 (en) 2008-01-15
AU7443901A (en) 2001-12-11
ATE494004T1 (de) 2011-01-15
EP1301202A4 (de) 2005-01-05
WO2001091698A3 (en) 2002-04-11
DE60143799D1 (de) 2011-02-17
WO2001091698A2 (en) 2001-12-06
EP1301202B1 (de) 2011-01-05

Similar Documents

Publication Publication Date Title
IL136511A0 (en) Genetically engineered mhc molecules
Bellgrau et al. A role for CD95 ligand in preventing graft rejection
AU6063500A (en) Glycoprotein vi and uses thereof
WO2006023148A3 (en) Genetically modified human natural killer cell lines
DE69528894D1 (de) Bifunktionelles protein, herstellung und verwendung
DK0726952T3 (da) Receptor benævnt ACT-4 på overfladen af aktiverede T-celler
EP1209237A3 (de) Synthetische DNA-Sequenz mit verstärkter isektizider Aktivität in Mais
DE69841110D1 (de) Verlängerte cdns, die für sekretierte proteine kodieren
NZ527297A (en) Immunosuppression by blocking T cell co-stimulation signal 2 (B7/CD28 interaction)
WO2001018035A3 (en) Muc-1 derived peptides
WO2002029060A3 (en) Hematopoietin receptors hpr1 and hpr2
WO2001036623A3 (en) Ecdysone-inducible adeno-associated virus expression vectors
NZ514975A (en) Improvement of T cell mediated immunity
AU2019312882A1 (en) Nucleic acid construct
EP0706319A4 (de) Retrovirale vektoren mit der fähigkeit zur expression multimerer proteine von mehreren translationsinitiations-orten
ES2152313T3 (es) Gen grb-3-3, sus variantes y sus utilizaciones.
WO2004035799A3 (de) Virale vektoren und deren verwendung für die gentherapie
ATE386049T1 (de) Epstein-barr virus type b ctl epitopen
AU5423898A (en) Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
WO2000052164A3 (en) Potassium channel molecules and uses therefor
WO2001055103A3 (en) Chimeric neuropeptide y receptors
SG54291A1 (en) Monoclonal antibodies to antigens expressed by hematopoietic facilitatory cells
DK1377667T3 (da) Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme
Bosco et al. TCR‐β chains derived from peripheral γδ T cells can take part in αβ T‐cell development
Zamoyska et al. Unprimed T cells are inefficiently stimulated by glycosylphosphatidylinositol-linked H-2Kb because of its lipid anchor rather than defects in CD8 binding